Here's Why Haemonetics (HAE) is a Strong Momentum Stock

分组1 - Zacks Premium offers various tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores provide a rating system for stocks based on value, growth, and momentum characteristics, helping investors identify securities with high potential for market outperformance [2][3] 分组2 - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E and Price/Sales, appealing to value investors [3] - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected earnings and sales for long-term growth potential [4] - The Momentum Score assists investors in capitalizing on price trends by evaluating recent price changes and earnings estimate revisions [5] 分组3 - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6] - The Zacks Rank, a proprietary stock-rating model, utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.81% since 1988, significantly outperforming the S&P 500 [7][8] 分组4 - To optimize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering the direction of earnings estimate revisions [9][10] - Haemonetics Corporation, which provides blood management solutions, is currently rated 3 (Hold) on the Zacks Rank but has a VGM Score of A and a Momentum Style Score of B, with shares increasing by 13.6% over the past four weeks [11][12] - Analysts have raised their earnings estimates for Haemonetics, with the Zacks Consensus Estimate increasing by $0.13 to $4.93 per share, indicating a positive outlook for the company [12][13]